The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab govitecan in combination with capecitabine for the treatment of advanced gastrointestinal cancers after progression on standard therapy.
 
Maria Diab
Consulting or Advisory Role - AstraZeneca; Guardant Health; Novartis
Research Funding - Bristol Myers Squibb Foundation; Gilead Sciences (Inst)
 
Sunita Ghosh
No Relationships to Disclose
 
Gazala Khan
Honoraria - Helsinn Therapeutics/QED Therapeutics; Helsinn Therapeutics/QED Therapeutics; Incyte; Pfizer; QED Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - UCANCERVIVE
Travel, Accommodations, Expenses - Helsinn Therapeutics
 
Zaid Al Saheli
No Relationships to Disclose
 
Ira Wollner
No Relationships to Disclose
 
Philip Philip
Honoraria - Astellas Pharma; Bayer; BioNTech SE; incyte; Ipsen; Novocure; Seagen; SERVIER; Taiho Pharmaceutical; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Incyte
Research Funding - Bayer (Inst); BioNTech SE (Inst); Genentech (Inst); halozyme (Inst); incyte (Inst); Lilly (Inst); Merck (Inst); merus (Inst); novartis (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals